Wednesday, 31 October 2012

Statin treatment is associated with a higher death rate and a higher risk of heart attack in angioplasty patients

This study was published in the New England Journal of Medicine 1994 Nov 17;331(20):1331-7
 
Study title and authors:
Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group.
Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB 3rd, Ivanhoe R, Cedarholm JC, Stillabower ME, Talley JD, DeMaio SJ
Department of Medicine, Emory University School of Medicine, Atlanta, GA.
 
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/7935702

This six month, randomized, double-blind trial evaluated the effects of lovastatin in 404 patients who had undergone angioplasty. (Angioplasty is the technique of mechanically widening narrowed or obstructed arteries). The patients received either lovastatin (40 mg orally twice daily) or placebo.

The study found:
(a) Patients receiving lovastatin had a 200% increased risk of death compared to the patients receiving placebo.
(b) Patients receiving lovastatin had a 177% increased risk of a heart attack compared to the patients receiving placebo.

The data from the study reveals that statin treatment is associated with a higher death rate and a higher risk of heart attack in angioplasty patients.

Monday, 29 October 2012

Increasing dietary saturated fat is associated with a reduction in breast cancer risk

This study was published in the American Journal of Epidemiology 1992 Dec 1;136(11):1327-37
 
Study title and authors:
Diet in the epidemiology of postmenopausal breast cancer in the New York State Cohort.
Graham S, Zielezny M, Marshall J, Priore R, Freudenheim J, Brasure J, Haughey B, Nasca P, Zdeb M.
Department of Social and Preventive Medicine, State University of New York 14214.
 
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/1336931

The study investigated the association of dietary fat consumption with the risk of breast cancer. The dietary histories of 18,586 postmenopausal women were analysed over a seven year period.

Regarding saturated fat consumption, the study found that for every 10 gram per day increase in saturated fat there was a 10% reduction in the risk of breast cancer.

Sunday, 28 October 2012

Statins double the risk of death in patients with coronary artery disease

This study was published in the Annals of Internal Medicine 1993 Nov 15;119(10):969-76

Study title and authors:
Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).
Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LW, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ; MARS Research Group.
University of Southern California, Los Angeles.

This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/8214993

This randomized, double-blind, placebo-controlled, multicenter study assessed the effects of lovastatin in patients with coronary artery disease. The trial included 270 patients, 37 to 67 years old who received either 80 mg/day of lovastatin, or placebo.

The study found that the patients receiving lovastatin had a 104% increased risk of death.

Statins are associated with higher death rates, higher cardiac death rates and increased risk of cancer

This study was published in Circulation 2000 Oct 10;102(15):1748-54
 
Study title and authors:
Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).
Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, Dzavik V, Taylor D, Yokoyama S, Montague TJ.
University of Alberta Hospitals, Edmonton, Alberta, Canada. teok@fhs.mcmaster.ca
 
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/11023927

One of the aims of this long-term, multicenter, randomized, double-blind, placebo-controlled trial was to evaluate the effects of simvastatin in patients with normal cholesterol levels and with detectable plaque build up in at least three major coronary artery segments. The study lasted for four years and included  a total of 460 patients: 230 received simvastatin and 230, a placebo.

The study found:
(a) The patients receiving simvastatin had a 117% increased risk of death compared to the patients receiving placebo.
(b) The patients receiving simvastatin had a 76% increased risk of cardiac death compared to the patients receiving placebo.
(c) The patients receiving simvastatin had a 225% increased risk of non-cardiac death compared to the patients receiving placebo.
(d) The patients receiving simvastatin had a 9% increased risk of a heart attack compared to the patients receiving placebo.
(e) The patients receiving simvastatin had a 78% increased risk of cancer compared to the patients receiving placebo.

The data from the study reveals that statins are associated with higher death rates, higher cardiac death rates and increased risk of cancer. 

Saturday, 27 October 2012

How soy phytosterols are manufactured. Would you really want to feed your family this processed poison?

This paper was published in Bioresource Technology 2010 Mar;101(5):1471-6
 
Study title and authors;
Recovery of phytosterols from waste residue of soybean oil deodorizer distillate.
Yang H, Yan F, Wu D, Huo M, Li J, Cao Y, Jiang Y.
Key Laboratory of Hollow Fiber Membrane Materials and Processes of the Ministry of Education, School of Material Science and Chemical Engineering, Tianjin Polytechnic University, Tianjin 300160, PR China.
 
This paper can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/19800221
 
This study describes a crystallization process used to recover soy phytosterols from the waste residue of soybean oil deodorizer distillate (WRSODD).
 
Where does the waste residue of soybean oil deodorizer distillate originate from?
 
Intially oil is extracted from soybeans using a solvent called hexane. (Hexane is a chemical byproduct of gasoline refining and has been identified by the FDA as a potent neurotoxin and a carcinogen.).  The oil is then refined, sometimes hydrogenated and is sold as vegetable oil, or ends up in a wide variety of processed foods. The refining process includes (i) degumming, (ii) neutralization, (iii) bleaching and (iv) deodorization.
 
(i) Degumming:
Crude soy oil contains gums such as phospholipids and other compounds that require removal before the deodorization stage, as they cause the oil to darken when heated. Extracted phospholipids are sold as lecithin. Solvents such as phosphoric acid and acetic anhydride are used in the degumming process. (Phosphoric acid is a corrosive acid and can form toxic fumes whact with other compounds. Acetic anhydride causes skin and eye burns and irritation of the respiratory tract. Nausea and vomiting may develop after exposure).
 
The degumming process itself also has undesirable effects such as contaminating oil with inorganic phosphates, degrading recovered phospholipids, and corroding stainless steel equipment.
 
(ii) Neutralization:
The degummed oil undergoes neutralization with a caustic alkaline solution followed by acid treatment. There are concerns that neutralization impairs the nutritional quality of oils, particularly the vitamin, mineral and protein content, and also adds potential carcinogenic compounds such as nitrosamines.
 
(iii) Bleaching:
The neutralized oil is then bleached which has the unfortunate effects of removing nutrients such as carotenoids and causing the fatty acids to go rancid.
 
(iv) Deodorization:
After the bleaching process, the oil is deodorized which eliminates beneficial components such as tocopherols from the oil.
 
Soybean oil deodorizer distillate is a waste product of the above soybean oil refining process. The soy
phytosterols are then removed from the soybean oil deodorizer distillate by various solvents.
 
This study describes various solvents used in the phytosterol removal process.
(a) Ethanol:
Ethanol is another name for alcohol. E.g most wines contain less than about 13% ethanol. A denaturant is added to industrial ethanol, which is a substance which makes the ethanol both unpalatable and poisonous.
 
(b) n-propanol:
Can injure eye tissue, cause skin irritation and may aggravate asthma-like conditions. In laboratory studies n-propanol has been shown to lower male fertility, harm the fetus and cause an increase in cancer.

(c) Hexane:
Hexane exposure has been linked with skin irritation, dry skin, pain in skin, irritation, pain and redness in eyes, abdominal pain, nausea, vomiting, drowsiness, dizziness, dullness, weakness, headache, upper airway irritation, breathing difficulty, muscle cramps, tinnitus, muscle wasting and symptoms of peripheral neuropathy in cases of chronic exposure.

Hexane can also cause cancer, and other serious health illnesses including reproductive and birth defects. Hexane has been linked to explosions in food processing units. It is a potent neurotoxin causing dangerous health effects in workers of food processing units.

(d) Cyclohexane:
Causes skin irritation, drowsiness, dizziness and may be fatal if swallowed and enters the airways.

(e) Petroleum ether (benzine):
Petroleum ether is a flammable liquid obtained in distilling petroleum and is used in cleaning and dyeing and as a motor fuel.

(f) Acetone:
May cause irritation to the eyes throat and respiratory system, mood swings, and nausea. In laboratory studies acetone has been shown to cause anemia and an increase in malformed sperm.

(g) Butanone:
Butanone is an irritant, causing irritation to the eyes and nose. Butanone has induced birth defects, liver tumours and mammary gland tumours in laboratory studies.

(h) Cyclohexanone:
Exposure to cyclohexanone can result in irritation to the eyes, nose, throat and skin. It may cause dizziness and unconsciousness. Studies have shown that cyclohexanone may cause cataracts.

(i) Benzene:
Benzene increases the risk of cancer, bone marrow failure and anemia.

(j) Toluene:
Toluene may cause liver, kidney neurological damage. It has been linked with irritation to the nose, throat and respiratory tract. Exposure to toluene may cause hallucinations, dizziness, drowsiness, slurred speech, tremors, respiratory depression, arrhythmias and convulsions. Coma and death can occur following substantial exposures.

After the soy phytosterols have been extracted by the above processes they are added to processed foods such as margarines, mayonnaises, vegetable oils, salad dressings, soy milk, orange juice, snack bars, low-fat milk and low-fat and non-fat beverages.
 
Is it healthy to eat these products that are manufactured in such an industrial manner? 

Friday, 26 October 2012

Statin treatment increases the risk of death by 301% after balloon angioplasty

This study was published in the Journal of the American College of Cardiology 1997 Oct;30(4):863-9
 
Study title and authors:
Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
Bertrand ME, McFadden EP, Fruchart JC, Van Belle E, Commeau P, Grollier G, Bassand JP, Machecourt J, Cassagnes J, Mossard JM, Vacheron A, Castaigne A, Danchin N, Lablanche JM.
Division of Cardiology B, Hôpital Cardiologique, Lille, France. bertrandme@AOL.com
 
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/9316510

This study investigated the effects of pravastatin treatment after coronary balloon angioplasty. (Coronary angioplasty is accomplished using a balloon-tipped catheter inserted through an artery in the groin or arm to enlarge a narrowing in a coronary artery). In a multicenter, randomized, double-blind trial, 695 patients were randomized to receive pravastatin (40 mg/day) or placebo for 6 months after successful balloon angioplasty.

The study found that the patients on statin treatment had a 301% increased risk of death compared to the patients receiving placebo.

Thursday, 25 October 2012

Children with predominant margarine consumption have an increased risk for eczema and allergic sensitization

This study can be accessed at Pediatric Allergy and Immunology 2006 Mar;17(2):85-93

Study title and authors:
Margarine and butter consumption, eczema and allergic sensitization in children. The LISA birth cohort study.
Sausenthaler S, Kompauer I, Borte M, Herbarth O, Schaaf B, Berg A, Zutavern A, Heinrich J; LISA Study Group.
GSF - National Research Centre for Environment and Health, Institute of Epidemiology, Neuherberg, Germany.

This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/16618357

The aim of the study was to assess the relationship between dietary intake of margarine and butter with eczema and allergic sensitization in two-year-old children. (Allergic sensitization is the development of antibodies to a substance that results in an allergic reaction). Data was analysed of the butter and margarine intake of 2,582 two-year-old children and the subsequent allergic outcome.

The study found:
(a) Predominant margarine intake was associated with a 110% increased risk of doctor-diagnosed eczema.
(b) Predominant margarine intake was associated with a 110% increased risk of allergic sensitization against inhalant allergens.
(c) No associations were found for butter intake.

The study shows that children with predominant margarine consumption had an increased risk for eczema and allergic sensitization, while butter intake was no predictor for allergic diseases.